News and Events

Keep up-to-date on recent events, webinars and releases from ArcherDX.



Oct
18
2018

Webinar: Validation of Error-Corrected Sequencing for Hematological Malignancies

In this webinar, Drs. Catherine Rehder and Sarah Rapisardo at Duke University describes their efforts to validate the Archer® VariantPlex® Myeloid assay. They also discuss their work to expand testing with a custom Archer FusionPlex® assay to detect known and novel fusions, with a focus on Ph-like ALL fusions.


Oct
11
2018

Archer at AMP 2018

ArcherDX at the Association for Molecular Pathology annual meeting in San Antonio, TX from November 1-3, 2018


Oct
3
2018

Press release: Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

ArcherDX and Merck KGaA, Darmstadt, Germany have entered into an agreement to develop and commercialize a next generation sequencing (NGS)-based companion diagnostic (CDx) assay.


Apr
12
2018

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).


Mar
30
2018

2018 Calendar of Events

Where in the world is ArcherDX? Archer will be traveling to multiple conferences around the world again this year. We hope to see you!


Mar
30
2018

Archer announces the 2018 Research Challenge Grant Winners

Archer awards 5 recipients up to 96 free reactions (12 kits with 8 reactions each) of an Archer Assay in the fields of mutation tracking, liquid biopsy and immune repertoire.


Mar
26
2018

Press release: ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services

ArcherDX and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX’s next-generation sequencing (NGS) assays.


Mar
20
2018

Press release: ArcherDX Closes $35 Million Series A Financing

ArcherDX, Inc. announces that it has closed a $35 million Series A Preferred financing.


Feb
5
2018

2018 Research Challenge Grant

ArcherDX will award 96 reactions (12 kits) each to 3 recipients in the categories of mutation tracking, liquid biopsy and immune repertoire


Dec
20
2017

2017 Company Overview

This year has proven to be exciting for ArcherDX, and we look forward to continuing this momentum into 2018. Some highlights include: ISO certification, CDx partnership with Celgene, new NGS-based myeloid assays, BCR sequencing assays, adoption of Reveal ctDNA kits, rapidly customizable panels, and software and analysis updates for an even greater level of variant calling confidence.


Dec
19
2017

2017 Publications Spotlight

2017 Publications Spotlight


Dec
5
2017

Archer at ASH 2017

ArcherDX at the American Society of Hematology in Atlanta, GA from December 9-12, 2017


Nov
14
2017

Press release: ArcherDX receives EN ISO 13485 certification for medical device quality management

ArcherDX announces ISO 13485:2003 & EN ISO 13485:2012 certification indicating that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic (IVD) assays


Nov
10
2017

Press release: ArcherDX, Celgene ink CDx development agreement

ArcherDX, Celgene ink worldwide companion diagnostic agreement relating to investigational drug CC-122


Oct
6
2017

ArcherDX at AMP 2017

Boost your molecular pathology research with Archer NGS assays, presenting at AMP 2017, Salt Lake City, UT Nov 16-18, Booth #1619


Oct
5
2017

Webinar - Archer VariantPlex myeloid assays

In this webinar we discuss how updates to the assay and software provide better coverage over challenging regions and enable lower limits of detection, high-resolution CNV detection and lightning-fast analysis that leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays.


Aug
2
2017

ArcherDX expands blood-based mutation assay portfolio with new myeloid panels

ArcherDX launches two new NGS-based NGS-based variant-detection assays, the 37-gene VariantPlex Core Myeloid and 72-gene VariantPlex Myeloid panel with unprecedented levels of confident mutation detection.


Jun
12
2017

ArcherDX presents at EHA 2017 in Madrid, Spain

ArcherDX presents at the 22nd European Hematology Association Congress in Madrid, Spain


Apr
24
2017

Archer sponsors Breast Cancer research platform

ArcherDX is partnering with Susan G. Komen Colorado and the University of Colorado Cancer Center to create a local event to connect community physicians, patients, and advocates with academic researchers and industry leaders. Our vision is to provide an educational forum to raise awareness about advances in breast cancer research, treatment, and testing.


Apr
20
2017

Archer at Immunology 2017

Archer exhibits at the American Association of Immunologists Annual Meeting–Immunology 2017 in Washington, DC. At the largest annual gathering of immunologists worldwide, scientists discuss breakthroughs across the full spectrum of topics in the Immunology.


Apr
19
2017

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017

Archer attends the Children's Oncology Group Cytogenetics Workshop 2017


Apr
19
2017

Archer presents workshop at Biomarkers and Immuno-Oncology World Congress 2017

We'll be exhibiting at Cambridge Healthtech Institute’s Thirteenth Annual Biomarkers and Immuno-Oncology World Congress and will presenting a poster and a workshop featuring on B- and T-Cell Immune Repertoire Characterization by Anchored Multiplex PCR and Next-Generation Sequencing. This conference is dedicated to all areas of biomarker research and development spanning the pharmaceutical and diagnostic pipelines.


Apr
18
2017

Archer at 106th Annual Meeting of Japanese Society of Pathology in Tokyo

We'll be co-attending with Illumina at the inaugural Japanese Society of Pathology in Tokyo. We'll be presenting five posters at this event and giving away corresponding poster flyers with the lead scientist contact info for later review. This gathering will strive to establish a focus on diagnosis that is based on an integrated understanding of disease through the use of high-sensitivity, high-volume analytical technologies like next-generation sequencers and embrace the ideal of giving something back to medicine and society as the goal of pathology.


Apr
3
2017

Meet us at the Rocky Mountain Blood Cancer Conference

Archer is Denver on April 8th promoting awareness of NGS in blood cancer cancer research at the Rocky Mountain Blood Cancer Conference hosted by the Leukemia and Lymphoma Society. This a free educational conference for patients, survivors, caregivers and healthcare professionals.

Subscribe to stay in the loop







How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.